NCT03834584View on ClinicalTrials.gov

A Study of AG-636 in the Treatment of Subjects With Advanced Lymphoma

PHASE1TerminatedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

May 24, 2019

Primary Completion Date

June 17, 2020

Study Completion Date

June 17, 2020

Conditions
Lymphoma
Interventions
DRUG

AG-636

AG-636 will be administered orally intermittently in 28-day cycles.

Trial Locations (6)

10065

Memorial Sloan Kettering Cancer Center, New York

Weill Cornell Medical Center, New York

33612

Moffitt Cancer Center, Tampa

68198

University of Nebraska Medical Center, Omaha

98109

Seattle Cancer Care Alliance, Seattle

06519

Yale Cancer Center, New Haven

Sponsors
All Listed Sponsors
lead

Agios Pharmaceuticals, Inc.

INDUSTRY